Related Experiment Video

Updated: Jul 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Management of patients with HBeAg-negative chronic hepatitis B

Nripen Saikia1, Rupjyoti Talukdar, Subhasish Mazumder

  • 1Department of Gastroenterology, Pushpawati Singhania Research Institute, New Delhi, India. saikia.n@gmail.com

Postgraduate Medical Journal
|February 3, 2007
PubMed

Insights

Hepatitis B e antigen-negative (HBeAg-negative) chronic hepatitis B (CHB) presents a treatment challenge, particularly in certain regions. This review examines current and emerging therapies for HBeAg-negative CHB, focusing on their effectiveness.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) is a major global health concern causing significant morbidity and mortality.
  • The emergence of hepatitis B e antigen-negative (HBeAg-negative) mutant strains poses a therapeutic challenge due to reduced responsiveness to existing treatments.
  • HBeAg-negative CHB is associated with rapid progression to liver cirrhosis and its complications.

Purpose of the Study:

  • To review and analyze approved and investigational treatment options for HBeAg-negative chronic hepatitis B.
  • To evaluate the efficacy of various therapeutic strategies against HBeAg-negative CHB.

Main Methods:

  • Systematic literature review of approved and under-trial treatments for HBeAg-negative CHB.
  • Analysis of clinical data and reported efficacies of different therapeutic agents.

Main Results:

  • HBeAg-negative CHB demonstrates less susceptibility to conventional antiviral therapies.
  • Certain novel therapeutic agents show promise in managing HBeAg-negative CHB, though further research is ongoing.
  • Treatment outcomes vary significantly based on the specific drug and patient population.

Conclusions:

  • HBeAg-negative CHB requires tailored treatment approaches due to its unique characteristics and resistance patterns.
  • Ongoing research into new therapies is crucial for improving outcomes in patients with HBeAg-negative CHB.
  • Effective management of HBeAg-negative CHB is essential to prevent disease progression and reduce liver-related complications.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...